Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
On Thursday, BD (Becton, Dickinson and Company) (NYSE:BDX) reported second-quarter sales of $5.04 billion, up 4.6% year over year, in line with the consensus.
周四，BD（贝克顿、狄金森公司）（纽约证券交易所代码：BDX）公布第二季度销售额为50.4亿美元，同比增长4.6％，符合市场共识。
"Second quarter performance reflects our strategy in action and the strength of our diverse portfolio," said Tom Polen, chairman, CEO and president of BD. "Our focus on BD Excellence and execution enabled strong operating margin and cash flow within the quarter. We enter the back half of fiscal 2024 with continued momentum giving us the confidence to again raise our fiscal 2024 earnings guidance as we deliver on our BD 2025 commitments."
BD董事长、首席执行官兼总裁汤姆·波伦表示：“第二季度的业绩反映了我们的行动战略以及我们多元化投资组合的实力。”“我们对BD卓越和执行的关注使本季度内实现了强劲的营业利润率和现金流。我们以持续的势头进入2024财年后半年，这使我们有信心在兑现2025年财年承诺的同时再次提高2024财年的收益预期。”
BD Medical segment sales increased $2.5 billion, up 3.8% (+3.7% organic), BD Life Sciences sales were up $1.3 billion, up 2.2% (+2.3%), and BD Interventional sales were up 9% (+13.6%) to $1.29 billion.
BD Medical板块的销售额增长了25亿美元，增长了3.8％（有机增长3.7％），BD生命科学板块的销售额增长了13亿美元，增长了2.2％（+2.3％），BD介入销售额增长了9％（增长13.6％），达到12.9亿美元。
Guidance: Becton, Dickinson expects 2024 sales of ~$20.1 billion-$20.3 billion versus prior guidance of $20.2 billion-$20.4 billion and the consensus of $20.3 billion.
指导：贝克顿、狄金森预计，2024年的销售额约为201亿至203亿美元，而之前的预期为202亿至204亿美元，共识为203亿美元。
The company raised the adjusted EPS guidance to $12.95-$13.15, up from prior guidance of $12.82-$13.06 compared to the consensus of $12.95.
该公司将调整后的每股收益预期从之前的12.82-13.06美元上调至12.95美元至13.15美元，而市场普遍预期为12.95美元。
William Blair remains positive about BD's long-term prospects, writing, "we remain optimistic on the outlook for BD as the company appears to be well on its way to achieving its BD 2025 commitments," including its operating margin target, which is one of the key metrics investors are focused on.
威廉·布莱尔仍然对BD的长期前景持乐观态度，他写道：“我们对BD的前景仍然乐观，因为该公司似乎正在顺利实现其2025年BD承诺”，包括其营业利润率目标，这是投资者关注的关键指标之一。
The recent increase in margins suggests potential for further improvement throughout the year, aligning with guidance and potentially reaching the 2025 target of around 25% by the end of fiscal 2024.
最近利润率的增长表明，全年都有进一步改善的潜力，与预期一致，有可能在2024财年末之前实现2025年约25％的目标。
Achieving this could lead to a slight increase in the company's valuation multiples, considering its current trading level at around 18 times the next twelve months (NTM) earnings, slightly below its three-year average of 20 times.
考虑到该公司目前的交易水平约为未来十二个月（NTM）收益的18倍，略低于其三年平均水平的20倍，实现这一目标可能会导致公司的估值倍数略有增加。
William Blair rates Becton, and Dickinson shares Outperform.
威廉·布莱尔对贝克顿的评级，狄金森的股票跑赢大盘。
Price Action: BDX shares are up 2.24% at $238.95 at the last check Thursday.
价格走势：在周四的最后一次检查中，BDX股价上涨2.24％，至238.95美元。